Literature DB >> 9838061

Anaphylatoxins C5a and C3a induce nuclear factor kappaB activation in human peripheral blood monocytes.

Z K Pan1.   

Abstract

The anaphylatoxins C5a and C3a are involved in the regulation of cytokine production. In this study the capability of C5a and C3a to induce transcription factor activation was examined. C5a and C3a stimulation of human peripheral blood monocytes resulted in nuclear expression of a DNA binding activity with specificity to the kappaB sequence. The p50 and p65 proteins, constituents of the prototypic nuclear factor kappaB, were identified as components of the DNA-protein complexes by anti-peptide antibodies in gel supershift assays. C5a induced kappaB binding activity was detected 15 min after agonist stimulation, peaked at 30-40 min, and remained detectable at 2 h. Binding to kappaB sequence was accompanied by an initial decrease and subsequent increase in the cytoplasmic IkappaBalpha levels, as detected by Western blotting using an anti-IkappaBalpha antibody. Pertussis toxin treatment markedly decreased kappaB binding activities induced by both C5a and C3a, whereas cholera toxin displayed no inhibitory effect. Neither of the two toxins affected kappaB binding activity induced by TNFalpha in the same cells. These results imply a potential role of the anaphylatoxins C5a and C3a in regulating leukocytes gene expression through G protein-coupled transcription factor activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9838061     DOI: 10.1016/s0167-4781(98)00198-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

Review 1.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

2.  Interleukin-8 induces nuclear transcription factor-kappaB through a TRAF6-dependent pathway.

Authors:  Sunil K Manna; Govindarajan T Ramesh
Journal:  J Biol Chem       Date:  2004-12-09       Impact factor: 5.157

3.  C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies.

Authors:  Al Carrera-Marín; Z Romay-Penabad; E Papalardo; E Reyes-Maldonado; E García-Latorre; G Vargas; T Shilagard; S Pierangeli
Journal:  Lupus       Date:  2012-08-29       Impact factor: 2.911

4.  Complement depletion enhances pulmonary inflammatory response after liver injury.

Authors:  Sean C Glasgow; Sathyabama Kanakasabai; Sabarinathan Ramachandran; T Mohanakumar; William C Chapman
Journal:  J Gastrointest Surg       Date:  2006-03       Impact factor: 3.452

Review 5.  Anaphylatoxins: their role in bacterial infection and inflammation.

Authors:  Pieter-Jan Haas; Jos van Strijp
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 6.  COVID-19: Complement, Coagulation, and Collateral Damage.

Authors:  Martin W Lo; Claudia Kemper; Trent M Woodruff
Journal:  J Immunol       Date:  2020-07-22       Impact factor: 5.422

7.  Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss.

Authors:  Michael X Hernandez; Shan Jiang; Tracy A Cole; Shu-Hui Chu; Maria I Fonseca; Melody J Fang; Lindsay A Hohsfield; Maria D Torres; Kim N Green; Rick A Wetsel; Ali Mortazavi; Andrea J Tenner
Journal:  Mol Neurodegener       Date:  2017-09-18       Impact factor: 14.195

8.  Complement anaphylatoxins C3a and C5a induce a failing regenerative program in cardiac resident cells. Evidence of a role for cardiac resident stem cells other than cardiomyocyte renewal.

Authors:  David Lara-Astiaso; Alberto Izarra; Juan Camilo Estrada; Carmen Albo; Isabel Moscoso; Enrique Samper; Javier Moncayo; Abelardo Solano; Antonio Bernad; Antonio Díez-Juan
Journal:  Springerplus       Date:  2012-12-12

9.  Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome.

Authors:  Arun Cumpelik; Barbara Ankli; Daniel Zecher; Jürg A Schifferli
Journal:  Ann Rheum Dis       Date:  2015-08-05       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.